Preprint Review Version 1 This version is not peer-reviewed

2017 FDA Peptide Harvest

Version 1 : Received: 9 April 2018 / Approved: 10 April 2018 / Online: 10 April 2018 (10:14:33 CEST)

A peer-reviewed article of this Preprint also exists.

Al Musaimi, O.; Al Shaer, D.; de la Torre, B.G.; Albericio, F. 2017 FDA Peptide Harvest. Pharmaceuticals 2018, 11, 42. Al Musaimi, O.; Al Shaer, D.; de la Torre, B.G.; Albericio, F. 2017 FDA Peptide Harvest. Pharmaceuticals 2018, 11, 42.

Journal reference: Pharmaceuticals 2018, 11, 42
DOI: 10.3390/ph11020042

Abstract

2017 was an excellent year in terms of new drugs (chemical entities and biologics) approved by the FDA, with a total of forty-six. In turn, one of the highlights was the number of peptides (six) included in this list. Here, the six peptides are analysed in terms of chemical structure, synthetic strategy used for their production, source, biological target, and mode of action.

Subject Areas

pharmaceutical market; drugs; drug discovery; solid-phase peptide synthesis

Readers' Comments and Ratings (1)

Comment 1
Received: 6 May 2018
Commenter: Zeyad
The commenter has declared there is no conflict of interests.
Comment: Hope all the best for you brother Al musaimi and alshaer
+ Respond to this comment
Leave a public comment
Send a private comment to the author(s)
Rate this article
Views 0
Downloads 0
Comments 1
Metrics 0
Leave a public comment

×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.